Bilateral facial weakness with paraesthesia variant of Guillain-Barré syndrome following Vaxzevria COVID-19 vaccine

Bonifacio, Guendalina; Patel, Dharmini; Cook, Sarah; Purcaru, Elena; Couzins, Michael; Domjan, J.; Ryan, Suzanne M.; Alareed, Ahmad W; Tuohy, Orla; Slaght, Seán J.; Furby, J; Allen, David J.; Katifi, Haider; Kinton, Lucy

doi:10.1136/jnnp-2021-327027

Cited by 57 publications

(52 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…AIDP was the most common electrophysiological variant encountered in this population, opposite to previous Mexican epidemiological reports, where axonal variants were more common in Mexican children (59% and 87.5%) ( Jackson et al, 2014 , Larrosa-Haro et al, 2010 ). Moreover, bilateral facial palsy was observed in more than half of our patients, a feature commonly observed in demyelinating subtypes, as reported in other GBS patients following the COVID-19 vaccine ( Bonifacio et al, 2021 ).…”

Section: Discussionsupporting

confidence: 86%

Guillain-Barré syndrome following SARS-CoV-2 vaccination: Is there a real association?

López-Hernández

Bazán-Rodríguez

Adib

et al. 2022

Neuroimmunology Reports

View full text Add to dashboard Cite

Background Guillain-Barre Syndrome (GBS) is the most common cause of acute flaccid paralysis, with an incidence of 0.81-1.89 cases per 100,000. With the SARS-CoV-2 virus pandemic, major international vaccination campaigns continue to be carried out to minimize the total burden of the disease. This study aims to report a case series of consecutive GBS patients after SARS-CoV-2 vaccination during the massive campaign in Mexico in 2021. Methods A single-center, observational study of consecutive GBS subjects diagnosed by Asbury criteria from January 1 to August 31, 2021. Including GBS-related symptoms on or after six weeks of vaccination record, both first and second doses. Results From a total of 53 GBS patients, eight had a history of SARS-CoV-2 vaccination, 87.5% male, the median vaccination-symptom onset and symptom-to-admission time were 15 (IQR 12.75-23.25), and 3.5 (IQR 1.5-8.25), all of them had GBS Disability Scale ≥3 at admission. Acute inflammatory demyelinating polyneuropathy (AIDP) was the most common electrophysiological variant encountered in this population. All patients received treatment Intravenous Immunoglobulin (IVIG) or Plasma Exchange (PE), 62.5% recovered independent walk at three months follow up. Conclusion The annual incidence of GBS cases associated with vaccination remains lower (0.81 - 1.89 cases / 100,000 persons) than non-vaccinated patients; this should encourage health authorities to continue promoting massive vaccination as benefits outweigh the risks.

show abstract

Section: Discussionsupporting

confidence: 86%

Guillain-Barré syndrome following SARS-CoV-2 vaccination: Is there a real association?

López-Hernández

Bazán-Rodríguez

Adib

et al. 2022

Neuroimmunology Reports

View full text Add to dashboard Cite

show abstract

“…All cases but one of GBS reported after adenovirus-vectored vaccine administration were associated with FP. [1][2][3][4][5] To confirm this pheno-…”

mentioning

confidence: 97%

“…This association may, however, be supported if postvaccination GBS displays a specific phenotype. Interestingly, 3 case series 1 , 2 , 3 have reported an associated facial paralysis (FP) in all cases of GBS developing after administration of the Oxford–AstraZeneca vaccine, a much higher frequency than expected. All cases but one of GBS reported after adenovirus‐vectored vaccine administration were associated with FP.…”

mentioning

confidence: 98%

“…All cases but one of GBS reported after adenovirus‐vectored vaccine administration were associated with FP. 1 , 2 , 3 , 4 , 5 To confirm this phenotype and substantiate the possible causal relationship, we compared herein the frequency of FP in cases of GBS (FP‐GBS) occurring after adenovirus‐vectored vaccines to that occurring after mRNA‐based vaccines using pharmacovigilance data.…”

mentioning

confidence: 98%

“…Although cases of Guillain–Barré syndrome (GBS) ensuing from COVID‐19 vaccination have been recently reported, 1 , 2 , 3 , 4 , 5 the development of GBS within 6 weeks of vaccination does not necessarily infer causation. This association may, however, be supported if postvaccination GBS displays a specific phenotype.…”

mentioning

confidence: 99%

See 2 more Smart Citations